- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 7, 2025
Product Development
PTC hits Huntington biomarker, but approval path still uncertain
Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | Dec 3, 2021
Distillery Therapeutics
Targeting CTNND2 phosphorylation for neuropathic pain
BioCentury | Aug 1, 2019
Product Development
NeuBase takes antisense oligos to more targets in more places
How NeuBase’s antisense oligo platform broadens the modality’s therapeutic horizons
BioCentury | May 17, 2019
Financial News
Actuate gets $21.7M to expand clinical testing of lead candidate
BioCentury | Mar 30, 2018
Clinical News
AMO Pharma reports Phase II data for myotonic dystrophy candidate
Items per page:
1 - 10 of 34